TScan Therapeutics (TCRX) Total Liabilities (2020 - 2025)
Historic Total Liabilities for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $118.2 million.
- TScan Therapeutics' Total Liabilities fell 61.88% to $118.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.2 million, marking a year-over-year decrease of 61.88%. This contributed to the annual value of $130.1 million for FY2024, which is 731.02% up from last year.
- Latest data reveals that TScan Therapeutics reported Total Liabilities of $118.2 million as of Q3 2025, which was down 61.88% from $121.8 million recorded in Q2 2025.
- TScan Therapeutics' 5-year Total Liabilities high stood at $130.1 million for Q4 2024, and its period low was $20.8 million during Q2 2022.
- Its 5-year average for Total Liabilities is $86.6 million, with a median of $117.9 million in 2024.
- Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 5490.97% in 2022, then skyrocketed by 50837.07% in 2023.
- Over the past 5 years, TScan Therapeutics' Total Liabilities (Quarter) stood at $27.3 million in 2021, then surged by 264.66% to $99.7 million in 2022, then increased by 21.7% to $121.3 million in 2023, then rose by 7.31% to $130.1 million in 2024, then dropped by 9.18% to $118.2 million in 2025.
- Its Total Liabilities was $118.2 million in Q3 2025, compared to $121.8 million in Q2 2025 and $122.5 million in Q1 2025.